New Sucampo Amitiza launch squeezes $10m milestone out of Takeda
This article was originally published in Scrip
Maryland, US-based biopharmaceutical company, Sucampo Pharmaceuticals has received a $10m milestone payment from its collaborative partner, Takeda Pharmaceutical on the launch of Amitiza in the US for another indication.
You may also be interested in...
Infographic: There are two CAR-T therapies on the market, both of which secured their first approvals in 2017. The pipeline of autologous and allogeneic CAR-T options is busy with several candidates in clinical studies. However, getting approval is only one part of getting these breakthrough therapies to patients.
Dmitry Kuzmin, managing partner, and Owen Smith, investment director, talk to In Vivo about 4BIO’s approach to venture investing in the biopharma sector: successes, red flags and targets for its second fund.
In the most recent installment of In Vivo's VC Playbook column, former Amgen R&D lead Sean Harper talks exclusively about his new role as a venture capitalist, joining veteran industry investor Beth Seidenberg as co-founder of Los Angeles-based Westlake Village BioPartners.